Abstract
Minnesota acute graft versus host disease (AGVHD) risk score is a validated tool to stratify newly-diagnosed patients into standard-risk (SR) and high-risk (HR) groups with ~85% having SR AGVHD. We aimed to identify factors for further risk-stratification within Minnesota SR patients. A single-center, retrospective analysis of consecutive patients between 1/2010 and 12/2014 was performed. Patients who developed AGVHD within 100 days and treated with systemic corticosteroids were included (N = 416), 356 (86%) of which were Minnesota SR and 60 (14%) had HR AGVHD. Isolated upper gastrointestinal (GI) AGVHD patients had significantly better day 28 and 56 CR/PR rates (90% vs. 72%, p = 0.004) and (83% vs 66%, p = 0.01), respectively, and lower 1-year non-relapse mortality (NRM; 10% vs. 22%; HR 0.4, p = 0.03). Lower GI AGVHD had less favorable outcomes with 1-year NRM of 40% (HR 2.1, p = 0.001), although CR/PR rates were not statistically different. In multivariate analysis, lower GI involvement (HR 2.6, p < 0.001), age ≥ 50 (HR 2.9, p < 0.001) and HCT-CI > 3 (HR 2.1, p = 0.002) predicted for 1-year NRM. Heterogeneity within Minnesota SR patients requires consideration in clinical trials, as distinct outcomes are observed in those with isolated upper GI and lower GI AGVHD, highlighting the importance of stratification in clinical trial design.
Highlights
-
Patients with Minnesota standard risk (SR) acute GVHD with isolated upper gastrointestinal involvement have excellent outcomes
-
Patients with lower gastrointestinal involvement have significantly worse NRM.
-
GI involvement can further refine the heterogeneity within the Minnesota SR patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41409-024-02393-1/MediaObjects/41409_2024_2393_Fig1_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41409-024-02393-1/MediaObjects/41409_2024_2393_Fig2_HTML.png)
Similar content being viewed by others
Data availability
Datasets of the analysis reported in this study are available from the corresponding author on reasonable request.
References
Reshef R, Saber W, Bolaños-Meade J, Chen G, Chen YB, Ho VT, et al. Acute GVHD diagnosis and adjudication in a multicenter trial: a report from the BMT CTN 1202 biorepository study. JCO. 2021;39:1878–87.
MacMillan ML, Robin M, Harris AC, DeFor TE, Martin PJ, Alousi A, et al. A refined risk score for acute GVHD that predicts response to initial therapy, survival and transplant-related mortality. Biol Blood Marrow Transpl. 2015;21:761–7.
Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, et al. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med. 2020;382:1800–10.
MacMillan ML, DeFor TE, Holtan SG, Rashidi A, Blazar BR, Weisdorf DJ. Validation of Minnesota acute graft-versus-host disease Risk Score. Haematologica. 2020;105:519–24.
Ardizzoia F, Lorentino F, Bruno A, Marktel S, Giglio F, Clerici D, et al. Minnesota acute graft-versus-host disease risk score predicts survival at onset of graft-versus-host disease after post-transplant cyclophosphamide prophylaxis. Haematologica. 2022;107:2748–51.
Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the mount Sinai acute GVHD International Consortium. Biol Blood Marrow Transplant. 2016;22:4–10.
Ferrara JLM, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373:1550–61.
Ramdial JL, Mehta RS, Saliba RM, Alousi AM, Bashir Q, Hosing C, et al. Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality. Bone Marrow Transpl. 2021;56:2005–12.
Pidala J, Hamadani M, Dawson P, Martens M, Alousi AM, Jagasia M, et al. Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. Blood. 2020;135:97–107.
Etra A, Capellini A, Alousi A, Al Malki MM, Choe H, DeFilipp Z, et al. Effective treatment of low-risk acute GVHD with itacitinib monotherapy. Blood. 2023;141:481–9.
MacMillan ML, Weisdorf DJ, Wagner JE, DeFor TE, Burns LJ, Ramsay NKC, et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transpl. 2002;8:387–94.
Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363:2091–101.
Castilla-Llorente C, Martin PJ, McDonald GB, Storer BE, Appelbaum FR, Deeg HJ, et al. Prognostic factors and outcomes of severe gastrointestinal GVHD after allogeneic hematopoietic cell transplantation. Bone Marrow Transpl. 2014;49:966–71.
Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9.
ElSawy M, Storer BE, Pulsipher MA, Maziarz RT, Bhatia S, Maris MB, et al. Multi-centre validation of the prognostic value of the haematopoietic cell transplantation- specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation. Br J Haematol. 2015;170:574–83.
Thakar MS, Broglie L, Logan B, Artz A, Bunin N, Burroughs LM, et al. The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases. Blood. 2019;133:754–62.
Raimondi R, Tosetto A, Oneto R, Cavazzina R, Rodeghiero F, Bacigalupo A, et al. Validation of the hematopoietic cell transplantation-specific comorbidity index: a prospective, multicenter GITMO study. Blood. 2012;120:1327–33.
Nikiforow S, Wang T, Hemmer M, Spellman S, Akpek G, Antin JH, et al. Upper gastrointestinal acute graft-versus-host disease adds minimal prognostic value in isolation or with other graft-versus-host disease symptoms as currently diagnosed and treated. Haematologica. 2018;103:1708–19.
Mariotti J, Granata A, Bramanti S, Devillier R, Furst S, Sarina B, et al. The new refined Minnesota risk score for acute graft-versus-host disease predicts overall survival and non-relapse mortality after T cell-replete haploidentical stem cell transplant with post-transplant cyclophosphamide. Bone Marrow Transpl. 2019;54:1164–7.
Major-Monfried H, Renteria AS, Pawarode A, Reddy P, Ayuk F, Holler E, et al. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. Blood. 2018;131:2846–55.
Srinagesh HK, Özbek U, Kapoor U, Ayuk F, Aziz M, Ben-David K, et al. The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. Blood Adv. 2019;3:4034–42.
Bidgoli A, DePriest BP, Saatloo MV, Jiang H, Fu D, Paczesny S. Current definitions and clinical implications of biomarkers in graft-versus-host disease. Transplant Cell Ther Off Publ Am Soc Transplant Cell Ther 2022;28:657–66.
Mielcarek M, Storer BE, Boeckh M, Carpenter PA, McDonald GB, Deeg HJ, et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood. 2009;113:2888–94.
Mielcarek M, Furlong T, Storer BE, Green ML, McDonald GB, Carpenter PA, et al. Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial. Haematologica. 2015;100:842–8.
Tarantino G, Saraceni F, Mancini G, Poiani M, Maroni L, Goteri G, et al. Gastrointestinal complications after allogeneic hematopoietic stem cell transplant: a multidisciplinary approach with early endoscopic evaluation. Clin Hematol Int. 2021;3:161–8.
Author information
Authors and Affiliations
Contributions
AMA and RMS conceived and designed the study. CM, AMA, LCH, and RMS collected and assembled the data. CM, AMA, and RMS wrote the manuscript. CM, AMA, JI, LCH, PS, UP, CH, PK, AO, RM, GC, MQ, ES, RCC, and RMM interpreted the data, approved the article and are accountable for publication.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Marcoux, C.M., Alousi, A.M., Im, J. et al. Gastrointestinal involvement refines prognosis in minnesota standard risk acute graft-vs.-host disease. Bone Marrow Transplant (2024). https://doi.org/10.1038/s41409-024-02393-1
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41409-024-02393-1